Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023
ページ情報: 英文 136 Pages
世界のペプチド合成の市場は予測期間中6.5%のCAGR (年間複合成長率) で推移し、2018年の3億1050万米ドルから、2023年には4億2640万米ドルの規模に成長すると予測されています。医薬品における利用の拡大、研究活動の活発化、R&D資金のアベイラビリティ、先進ペプチド合成装置の開発などの要因が同市場の成長を推進する見通しです。
The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. Factors such as increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market. However, the lack of a unified set of regulations for therapeutic peptides is expected to restrain the growth of this market during the forecast period.
By technology, the peptide synthesis market is segmented into solid-phase, liquid -phase, and hybrid & recombinant technology. Solid-phase synthesis is associated with a number of advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. Such advantages are expected to drive the adoption of solid-phase synthesis.
By end user, the market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic and research institutes. The contract development and manufacturing organizations segment is expected to grow at the highest CAGR during the forecast period. The increasing demand for cost-effective peptide synthesis services in drug development activities and life science research is driving the growth of this segment.
North America dominated the peptide synthesis market in 2017, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the peptide synthesis market. The large share of North America in this market can be attributed to the high prevalence of chronic diseases, increasing investments in the development of structure-based drug designs, and growing research in the fields of genomics and proteomics in the region.
Break of primary participants was as mentioned below:
The major players in the peptide synthesis market are: GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGAA (Germany) and New England Peptide (US).
The peptide synthesis market in this report is segmented by product, technology, end user, and regions. It provides detailed information regarding major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, new product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the peptide synthesis market.
From an insight perspective, this research report has focused on various levels of analysis-market share analysis of top players, company profiles which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the peptide synthesis market; high-growth regions; and market drivers, restraints, and opportunities. The report provides the latest peptide synthesis industry statistics and industry trends, allowing buyers to identify the high growth product segment and potential customers and suppliers hence driving revenue growth and profitability.
The report provides insights on the following pointers:
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.